The second key finding concerns the safety of post-osimertinib treatments following the onset of osimertinib-induced ILD; an overall ILD recurrence rate of 16% was associated with the EGFR-TKI rechallenge while a higher rate of 28% was associated with the osimertinib rechallenge. Here, EGFR is linked to interstitial lung disease.